These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Construction of a Bivalent Thrombin Binding Aptamer and Its Antidote with Improved Properties. Hughes QW; Le BT; Gilmore G; Baker RI; Veedu RN Molecules; 2017 Oct; 22(10):. PubMed ID: 29048375 [TBL] [Abstract][Full Text] [Related]
4. Post-SELEX optimization of aptamers. Gao S; Zheng X; Jiao B; Wang L Anal Bioanal Chem; 2016 Jul; 408(17):4567-73. PubMed ID: 27173394 [TBL] [Abstract][Full Text] [Related]
5. Molecular Engineering of Aptamer Self-Assemblies Increases Xia F; He A; Zhao H; Sun Y; Duan Q; Abbas SJ; Liu J; Xiao Z; Tan W ACS Nano; 2022 Jan; 16(1):169-179. PubMed ID: 34935348 [TBL] [Abstract][Full Text] [Related]
7. Artificial Intelligence in Aptamer-Target Binding Prediction. Chen Z; Hu L; Zhang BT; Lu A; Wang Y; Yu Y; Zhang G Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808496 [TBL] [Abstract][Full Text] [Related]
8. Effect of Chemical Modifications on Aptamer Stability in Serum. Kratschmer C; Levy M Nucleic Acid Ther; 2017 Dec; 27(6):335-344. PubMed ID: 28945147 [TBL] [Abstract][Full Text] [Related]
9. Aptamers: A Review of Their Chemical Properties and Modifications for Therapeutic Application. Adachi T; Nakamura Y Molecules; 2019 Nov; 24(23):. PubMed ID: 31766318 [TBL] [Abstract][Full Text] [Related]
11. Chimeric aptamers in cancer cell-targeted drug delivery. Kanwar JR; Roy K; Kanwar RK Crit Rev Biochem Mol Biol; 2011 Dec; 46(6):459-77. PubMed ID: 21955150 [TBL] [Abstract][Full Text] [Related]
12. Enhancing aptamer function and stability via in vitro selection using modified nucleic acids. Meek KN; Rangel AE; Heemstra JM Methods; 2016 Aug; 106():29-36. PubMed ID: 27012179 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, pharmacodynamics and safety of aptamers. Kovacevic KD; Gilbert JC; Jilma B Adv Drug Deliv Rev; 2018 Sep; 134():36-50. PubMed ID: 30321620 [TBL] [Abstract][Full Text] [Related]
14. Nucleic acid-based aptamers: applications, development and clinical trials. Kanwar JR; Roy K; Maremanda NG; Subramanian K; Veedu RN; Bawa R; Kanwar RK Curr Med Chem; 2015; 22(21):2539-57. PubMed ID: 25723512 [TBL] [Abstract][Full Text] [Related]
15. RNA and DNA aptamers in cytomics analysis. Ulrich H; Martins AH; Pesquero JB Curr Protoc Cytom; 2005 Aug; Chapter 7():Unit 7.28. PubMed ID: 18770826 [TBL] [Abstract][Full Text] [Related]
16. Assays for aptamer-based platforms. Citartan M; Gopinath SC; Tominaga J; Tan SC; Tang TH Biosens Bioelectron; 2012 Apr; 34(1):1-11. PubMed ID: 22326894 [TBL] [Abstract][Full Text] [Related]
17. Replacing antibodies with modified DNA aptamers in vaccine potency assays. Trausch JJ; Shank-Retzlaff M; Verch T Vaccine; 2017 Oct; 35(41):5495-5502. PubMed ID: 28433327 [TBL] [Abstract][Full Text] [Related]
18. Polyvalent nucleic acid aptamers and modulation of their activity: a focus on the thrombin binding aptamer. Musumeci D; Montesarchio D Pharmacol Ther; 2012 Nov; 136(2):202-15. PubMed ID: 22850531 [TBL] [Abstract][Full Text] [Related]
19. Aptamers: A Feasible Technology in Cancer Immunotherapy. Soldevilla MM; Villanueva H; Pastor F J Immunol Res; 2016; 2016():1083738. PubMed ID: 27413756 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic Properties of DNA Aptamers with Base Modifications. Gupta S; Drolet DW; Wolk SK; Waugh SM; Rohloff JC; Carter JD; Mayfield WS; Otis MR; Fowler CR; Suzuki T; Hirota M; Ishikawa Y; Schneider DJ; Janjic N Nucleic Acid Ther; 2017 Dec; 27(6):345-353. PubMed ID: 28961063 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]